Results 101 to 110 of about 6,317 (201)

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj  

Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review

Respirology Case Reports
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disorder characterized by necrotizing vasculitis, asthma, and eosinophilia. We report a case of EGPA that developed during benralizumab treatment for severe asthma and provide a ...
Mitsukuni Sakabe, Kazunori Tobino, Yumi Obata, Shota Sogabe, Kazuki Uchida, Yosuke Murakami   +5 more
doaj   +1 more source

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study

Frontiers in Allergy
IntroductionSevere eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients ...
Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D’Amato   +24 more
doaj   +1 more source

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Biologics: Targets & Therapy, 2019
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Caminati M, Bagnasco D, Vaia R, Senna G
doaj  

Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE

ERJ Open Research
Background In Europe, although multiple biologics have been approved for the treatment of severe asthma (SA), comparative data from real-world settings remain limited. This study compared the real-world effectiveness of dupilumab with that of omalizumab,
Giorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, Juby Jacob-Nara, Kinga Borsos, Richard H. Stanford, Zhixiao Wang, Mena Soliman, Lynn Huynh, Fariha Haque, Mei Sheng Duh, Wei-Han Cheng   +11 more
doaj   +1 more source

The effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world study [PDF]

Introduction: Add-on biological monoclonal antibodies such as benralizumab (anti-IL-5Ra) are recommended by international guidelines to reduce exacerbations in severe eosinophilic asthma (SEA).
Alves, Carolina da Silva, Duarte-Ramos, Filipa, Gerardo, António Madeira, Gomes, Margarida, Liberato, Hedi, Lopes, Carlos, Mendes, Ana, Pardal, Cecília, Sokolova, Anna, Tonin, Fernanda   +9 more
core   +1 more source

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Journal of Asthma and Allergy
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich ...
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K   +9 more
doaj  

Care pathways for the selection of a biologic in severe asthma [PDF]

, 2017
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Busse, William W, Cruz, Alvaro A, Djukanovic, Ratko, Domingo, Christian, Gow, Andrew Menzies, Hanania, Nicola A, Humbert, Marc, Phipatanakul, Wanda, Wahn, Ulrich, Wechsler, Michael E   +12 more
core   +2 more sources

Airway Occlusion Pressure Revisited. [PDF]

, 2020
Sassoon, Catherine S, Younes, Magdy
core  

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. [PDF]

OBJECTIVE: The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA).

core   +1 more source